152 related articles for article (PubMed ID: 533888)
1. Synthesis and biological evaluation of 9,11-azo-13-oxa-15-hydroxyprostanoic acid, a potent inhibitor of platelet aggregation.
Kam ST; Portoghese PS; Gerrard JM; Dunham EW
J Med Chem; 1979 Nov; 22(11):1402-8. PubMed ID: 533888
[TBL] [Abstract][Full Text] [Related]
2. 9, 11-Azo-12-oxa-15-hydroxyprostanoic acid: a potent thromboxane synthetase inhibitor and a PGH2/TxA2 receptor antagonist.
Kam ST; Portoghese PS
Prostaglandins Med; 1979 Nov; 3(5):279-90. PubMed ID: 233035
[TBL] [Abstract][Full Text] [Related]
3. 12-HETE inhibits the binding of PGH2/TXA2 receptor ligands in human platelets.
Fonlupt P; Croset M; Lagarde M
Thromb Res; 1991 Jul; 63(2):239-48. PubMed ID: 1837628
[TBL] [Abstract][Full Text] [Related]
4. Competitive antagonism at thromboxane receptors in human platelets.
Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
[TBL] [Abstract][Full Text] [Related]
5. Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists.
Hanasaki K; Arita H
Biochem Pharmacol; 1988 Oct; 37(20):3923-9. PubMed ID: 2973322
[TBL] [Abstract][Full Text] [Related]
6. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo.
Le Breton GC; Lipowski JP; Feinberg H; Venton DL; Ho T; Wu KK
J Pharmacol Exp Ther; 1984 Apr; 229(1):80-4. PubMed ID: 6423815
[TBL] [Abstract][Full Text] [Related]
7. Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H8-13. PubMed ID: 2409821
[TBL] [Abstract][Full Text] [Related]
8. The affinities of prostaglandin H2 and thromboxane A2 for their receptor are similar in washed human platelets.
Mayeux PR; Morton HE; Gillard J; Lord A; Morinelli TA; Boehm A; Mais DE; Halushka PV
Biochem Biophys Res Commun; 1988 Dec; 157(2):733-9. PubMed ID: 2974286
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid.
Gorman RR; Bundy GL; Peterson DC; Sun FF; Miller OV; Fitzpatrick FA
Proc Natl Acad Sci U S A; 1977 Sep; 74(9):4007-11. PubMed ID: 269449
[TBL] [Abstract][Full Text] [Related]
10. Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H1-7. PubMed ID: 3925795
[TBL] [Abstract][Full Text] [Related]
11. Photoaffinity receptor antagonist for human platelet thromboxane A2/prostaglandin H2 receptors.
Mais DE; Liel N; Halushka PV
Biochem Pharmacol; 1990 Oct; 40(7):1457-61. PubMed ID: 2145838
[TBL] [Abstract][Full Text] [Related]
12. Decrease in agonist affinity for human platelet thromboxane A2/prostaglandin H2 receptors induced by a platelet-derived supernatant.
Dorn GW; Burch RM; Kochel PJ; Mais DE; Halushka PV
Biochem Pharmacol; 1987 Jun; 36(12):1913-7. PubMed ID: 2954555
[TBL] [Abstract][Full Text] [Related]
13. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
Parise LV; Venton DL; Le Breton GC
J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669
[TBL] [Abstract][Full Text] [Related]
14. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
Gorman RR; Fitzpatrick FA; Miller OV
Biochem Biophys Res Commun; 1977 Nov; 79(1):305-13. PubMed ID: 200243
[No Abstract] [Full Text] [Related]
15. [Synthesis of thromboxane A2: limiting stages of primary thrombocyte aggregation in humans initiated by arachidonic acid and its metabolic products].
Mevkh AT; Basevich VV; Varfolomeev SD
Biokhimiia; 1984 Dec; 49(12):2035-40. PubMed ID: 6441604
[TBL] [Abstract][Full Text] [Related]
16. Prostaglandin H2 in human platelet activation: coactivator and substitute for thromboxane A2.
Hornberger WB; Patscheke H
Prog Clin Biol Res; 1989; 301():315-9. PubMed ID: 2798452
[TBL] [Abstract][Full Text] [Related]
17. Influence of trapidil derivatives on arachidonic acid- and prostaglandin endoperoxide analogue- induced platelet aggregation and thromboxane A2 formation.
Heinroth I; Block HU; Mest HJ
Biomed Biochim Acta; 1984; 43(8-9):S389-92. PubMed ID: 6440555
[TBL] [Abstract][Full Text] [Related]
18. Effect of OKY-046, a thromboxane A2 synthetase inhibitor, on arachidonate-induced platelet aggregation: possible role of "prostaglandin H2 steal" mechanism.
Kuzuya T; Hoshida S; Yamagishi M; Ohmori M; Inoue M; Kamada T; Tada M
Jpn Circ J; 1986 Nov; 50(11):1071-8. PubMed ID: 3102802
[TBL] [Abstract][Full Text] [Related]
19. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
Yin K; Halushka PV; Yan YT; Wong PY
J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin H2 directly lowers human platelet cAMP levels.
Rybicki JP; Le Breton GC
Thromb Res; 1983 Jun; 30(5):407-14. PubMed ID: 6310815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
